A structured exit strategydecreasing dose every 2 to 4 weeks over 8 to 12 weeksgives your body time to recalibrate its own GLP-1 receptor sensitivity and ghrelin production
reported that GLP1RAs, regardless of structural homology, reduced the risk of major adverse cardiovascular events (i.e., 3point major adverse cardiovascular events (MACE), including nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) by 14% (HR 0.86, 95% CI 0.800.93), allcause mortality by 12% (HR 0.88, 95% CI 0.820.94) and hospital admissions for heart failure by 11% (HR 0.89, 95% CI 0.820.98) [45]
But his insurance has never covered the medication, so he uses a cheaper, riskier form of GLP-1 thats not approved by the Food and Drug Administration
Understanding how GSH level and synthesis velocity depend on the sex hormones is an extremely important question since oxidative stress contributes to the risk for heart disease [8] and cancer [9] , and oxidative stress is reduced by GSH via the enzyme GPX [Figure 1]
SURMOUNT-1 trial (NCT04184622, estimated study completion in May 2024) is testing the ability of tirzepatide (at doses of 5, 10, or 15 mg) to reduce weight in subjects with diabetes and obesity at 72 weeks
